MedTrace Logo

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

NCT06608511 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-12-17

No results posted yet for this study

Summary

The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is:

* Are blood based signatures able to predict progression-free survival (PFS)?

Participants undergoing regular treatment for their skin cancer will provide blood samples.

Conditions

  • Skin Cancer
  • Melanoma (Skin Cancer)
  • Basal Cell Carcinoma of Skin
  • Basal Cell Carcinoma of Skin, Site Unspecified
  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Merkel Cell Carcinoma of Skin

Interventions

OTHER

Blood draw for the laboratory assessment

Participants will have 50 milliliters (3.5 tablespoons) of blood drawn

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Vincent Ma, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-11
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608511 on ClinicalTrials.gov